Considering that disrupted STAT3 activity due to aging and the neurotoxic effects of amyloid contribute to memory impairment associated with AD, the activation of STAT3 emerges as a novel therapeutic strategy for the condition. The gene discussed is STAT3; the disease is memory impairment.